ISSN: 0277-3732

Journal Home

Journal Guideline

American Journal of Clinical Oncology Q2 Unclaimed

Lippincott Williams and Wilkins Ltd. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

American Journal of Clinical Oncology is a journal indexed in SJR in Oncology and Cancer Research with an H index of 90. It has an SJR impact factor of 0,711 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,711.

American Journal of Clinical Oncology focuses its scope in these topics and keywords: cancer, patients, chemotherapy, therapy, breast, neoadjuvant, cell, stereotactic, radiotherapy, physical, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Oncology (Q2) Cancer Research (Q3)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

0,711

SJR Impact factor

90

H Index

87

Total Docs (Last Year)

334

Total Docs (3 years)

2755

Total Refs

645

Total Cites (3 years)

309

Citable Docs (3 years)

1.55

Cites/Doc (2 years)

31.67

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

International Journal of Oncology Q2
BMC Cancer Q2
Cancer Epidemiology Q2
Frontiers in Oncology Q2
Journal of Geriatric Oncology Q2

Compare this journals

Aims and Scope

Best articles by citations

Preoperative Radiotherapy for Cancer of the Extrahepatic Bile Duct

Gonadal Function Following ABVD Therapy for Hodgkin's Disease

Patterns of Long-term Cancer Survivorship Care in a National Cancer Institute-Designated Comprehensive Cancer Center

The Correlation Between Palliation of Bone Pain by Intravenous Strontium-89 and External Beam Radiation to Linked Field in Patients With Osteoblastic Bone Metastases

Treating Locally Advanced Cervical Cancer With Concurrent Chemoradiation Without Brachytherapy in Low-resource Countries

Docetaxel Plus 5-Fluorouracil in Locally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen

Evaluation of Multi Skin Test in Colorectal Cancer Patients and Effects of Serum Immunosuppressive Factor and Cytokine Production of Peripheral Mononuclear Cells

University of Miami Experience Using One Versus Two Intracavitary Brachytherapy Implants

Prognostic Features and Survival of Inoperable Hepatocellular Carcinoma in Turkish Patients With Cirrhosis

Placental Metastasis from Maternal Primitive Neuroectodermal Tumor

Subsets More Likely to Benefit From Surgery or Prophylactic Cranial Irradiation After Chemoradiation for Localized Non-Small-Cell Lung Cancer

SHOW MORE ARTICLES

The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer

Evaluation of the Clonality of Multilobar Bronchioloalveolar Carcinoma of the Lung

Metastatic Adenocarcinoma Arising in a Congenital Foregut Cyst of the Esophagus

Accelerated Epirubicin-Ifosfamide-Dacarbazine Regimen in Patients with Adult Soft Tissue Sarcomas

Postsurgical Etoposide-Ifosfamide Regimen in Poor-Risk Nonmetastatic Osteogenic Sarcoma

Does Stereotactic Eligibility for the Treatment of Glioblastoma Cause Selection Bias in Randomized Studies?

Computed Tomography Features of Cerebral Spread of Malignant Melanoma

Metastatic Angiosarcoma of the Spleen After Accidental Radiation Exposure

Daily Low-Dose Subcutaneous Recombinant Interleukin-2 by Alternate Weekly Administration

Announcements

Malignant Fibrous Histiocytoma of the Spermatic Cord

Efficacy of Zoledronic Acid and Pamidronate in Breast Cancer Patients: A Comparative Analysis of Randomized Phase III Trials